- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
ImmunoGen Inc+ Add to Watchlist
IMGN:US16.0401 USD 0.0301 0.19%
As of 14:45:57 ET on 03/12/2014.
Company Profile for ImmunoGen Inc (IMGN)
ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.
Key Executives for ImmunoGen Inc (IMGN)
|Daniel M Junius "Dan"President/CEO||David B Johnston "Dave"Exec VP/CFO|
|Charles Q Morris "Charlie"Exec VP/Chief Development Ofcr||John M LambertExec VP/Chief Scientific Ofcr|
|James J O'LearyVP/Chief Medical Officer||Ellie HarrisonVP/Chief Human Resources Ofcr|
|Craig BarrowsVP/Secretary/General Counsel||Peter J WilliamsVP:Business Development|
|Theresa G WingroveVP:Regulatory Affairs||Eric GuempelVP:Product Strategy|
|Carol HausnerExec Dir:Investor Relations|